A Biotech Finds a Solution to Lose Weight without Diet and Exercise

Wherever we go, we are often fed the idea of losing weight and looking good. Our society somehow values the ideal body above all else. Yet on the contrary, worldwide obesity has nearly tripled since 1975. In 2016, more than 1.9 billion adults aged 18 years and older were overweight (approximately 26% of the world population). In Canada, 5.3 million adults (20.2%) reported themselves as obese in 2014. Being obese or overweight is a growing issue in our sedentary and fast food filled lives.

Source: Statistics Canada

Novo Nordisk, a Danish multinational pharmaceutical company, has collaborated with Embark Biotech to find a treatment for obesity and its associated health effects. The goal is to create new drugs that can help people lose weight by burning off excess energy instead of storing it as fat. 

At first, Novo Nordisk created anti-obesity medications to help those with diabetes reduce their appetite and change the way their body absorbs food. The science behind Semaglutide is that it simulates human glucagon- like peptide hormones. Upon taking the drug, it reduces hunger and increases feelings of fullness . Utilizing Semaglutide, people will be able to control their eating habits and ultimately prompt weight loss.

Source: European Biotechnology

Although there is no current cure for diabetes, Semaglutide was approved as a treatment by the US Food and Drug Administration (FDA) in 2017, and by the European Commission, the Health Canada and the Japanese Ministry of Health, Labour and Welfare in 2018. After finding a drug that treats type 2 diabetes, Novo Nordisk tested its effects in promoting weight loss in obese adults without diabetes. Although still in its trail phase, Semaglutide has shown outstanding results. In a trial involving 957 participants who were given Semaglutide 0.4 mg administered once- daily via injections, 83% of the people lost greater than or equal to 5% of their body weight and 65% lost greater than or equal to 10%. 

The cure for obesity is near, with a combination of Semaglutide, exercise and clean eating. Although Semaglutide works without exercise and dieting, it is important to incorporate these activities into your daily life to become healthier and energized. Novo Nordisk and Embark Biotech are leading the way to finally diminish being obese or overweight.

Investing in the Digital Future

Coincapital offers investment products focused on emerging technologies including blockchain, digital currencies, AI and robotics.

Let's keep in touch

We help Canadians easily access the tremendous growth potential of these industries with products designed to fit in your everyday portfolio.

Stay up-to-date with the latest news and trends in technology investing by signing up for our monthly newsletter.